US Edition
Italfarmaco’s Duvyzat gains EC conditional approval for DMD treatment
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Italfarmaco’s Duvyzat gains EC conditional approval for DMD treatment
Duvyzat must be administered alongside corticosteroids and is not limited by the patient’s specific genetic mutation. The decision is applicable across all 27 EU member states, as well The post Italfarmaco’s Duvyzat gains EC conditional approval for DMD treatment appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium